Litcius/Paper detail

P47.11 COMPEL: Chemotherapy With/Without Osimertinib in Patients With EGFRm Advanced NSCLC and Progression on First-Line Osimertinib

Lecia V. Sequist, Nir Peled, Amanda Tufman, Leslie Servidio, J. Li, R. Taylor, Jun Zhao

2021Journal of Thoracic Oncology16 citationsDOIOpen Access PDF

Topics & Concepts

OsimertinibMedicineT790MLung cancerChemotherapyOncologyInternal medicineTyrosine-kinase inhibitorEpidermal growth factor receptorTyrosine kinaseCancer researchCancerReceptorErlotinibGefitinibLung Cancer Treatments and MutationsColorectal Cancer Treatments and StudiesGastric Cancer Management and Outcomes
P47.11 COMPEL: Chemotherapy With/Without Osimertinib in Patients With EGFRm Advanced NSCLC and Progression on First-Line Osimertinib | Litcius